Haploidentical Transplants with Post Transplant Cyclophosphamide

Haploidentical Transplants with Post Transplant Cyclophosphamide

Haploidentical stem-cell transplant with post-transplant cyclophosphamide in India using a partially matched donor, specialist GVHD prevention and transplant-unit monitoring.

✓Our healthcare experts will be by your side, helping you make the best treatment choice.

Related Conditions

Our services are FREE and by using our services your hospital bill does not increase!

About Haploidentical Transplants with Post Transplant Cyclophosphamide

Haploidentical transplantation with post-transplant cyclophosphamide (PTCy) in India is an allogeneic stem-cell transplant strategy that allows selected patients to receive cells from a partially HLA-matched donor, commonly a parent, child or sibling. PTCy is given shortly after transplantation as part of a protocol designed to reduce graft-versus-host disease (GVHD) risk.

Before transplant, the recipient undergoes disease-status assessment, organ-function testing, infection screening and transplant-fitness evaluation, while potential donors require HLA typing and independent medical assessment. The treatment pathway also includes conditioning therapy, stem-cell infusion, additional immunosuppression and close monitoring during marrow and immune recovery.

Important risks include infection, GVHD, graft failure, relapse and treatment-related organ toxicity. Eligibility depends on the diagnosis, disease status, previous treatment, donor options and overall health. New fever, severe diarrhoea, jaundice, breathing difficulty or rapidly worsening symptoms after transplant require urgent specialist assessment.

Cost in India depends on conditioning, donor work-up and HLA testing, stem-cell collection, transplant admission, protective isolation, medicines, blood-product support and management of complications. Major tertiary centres in India provide dedicated allogeneic transplant units, laboratory support and multidisciplinary haematology care. Medical Help India can connect international patients with an appropriate healthcare partner to review recipient and donor records, assess whether a PTCy-based haploidentical transplant is suitable and provide an individual hospital estimate.

What's Included

Pre-treatment consultation
Diagnostic tests & evaluation
Treatment procedure
Post-treatment care
Hospital stay (if required)
Follow-up consultations

Why consider treatment in India?

Access to experienced specialists

Advanced treatment and diagnostic options

More affordable hospital care

Shorter waiting times for treatment

Help comparing hospitals, plans and costs

Support with appointments, travel and follow-up

Cost in India

USD
$28,000–42,000

Final costs depend on the medical assessment, hospital, room category and clinical needs.

Get a Cost Estimate

How it works

1

Share your details

Tell us about your health concerns, age and current location.

2

Receive a call

We call you to discuss your situation, needs and questions.

3

Receive a treatment plan

Get information about the most suitable treatment plan, hospital and estimated cost.

4

Choose your plan

Review the options and agree on your care and travel plan.

5

Get full support

Receive full support throughout every stage of your care journey.

6

Receive care in India

Receive your planned care with support throughout your stay.

Top Hospitals for Haploidentical Transplants with Post Transplant Cyclophosphamide

View All Hospitals →

Frequently Asked Questions

How much does Haploidentical Transplants With Post Transplant Cyclophosphamide cost in India?

Cost depends on conditioning, donor work-up and HLA testing, stem-cell collection, transplant admission, protective isolation, medicines, blood-product support and management of complications. A prolonged admission or treatment of major transplant complications can substantially change the final estimate.

Which medical reports are useful to have ready for Haploidentical Transplants With Post Transplant Cyclophosphamide?

Have ready: the confirmed diagnosis, pathology or bone-marrow reports, disease-status testing, previous chemotherapy or radiotherapy summaries, recent blood counts and organ-function tests, infection screening, current medicines and available HLA and donor information. Include any prior transplant assessment or proposed conditioning plan.

What is post-transplant cyclophosphamide (PTCy)?

PTCy is cyclophosphamide given shortly after an allogeneic graft as part of a strategy to reduce harmful alloreactive immune cells and GVHD risk.

Is PTCy the whole transplant treatment?

No. It is one component of a broader protocol that includes conditioning, stem-cell infusion, additional immune suppression and close post-transplant monitoring.

Who may be considered for a PTCy-based haploidentical transplant?

Eligibility depends on the underlying disease, disease status, overall health, donor options and the transplant centre’s protocol.

Doctor discussing treatment options with a patient

Our services are FREE

We connect you with leading hospitals and specialists in India. You pay the hospital directly.

TelegramWhatsApp